[Profile]

• Education

  • Bachelor, Medicine; Kaohsiung Medical University,

• Career and Experience

  Current Positions：Experiences：
  • - Now, Attending physician, Allergy, Immunology and Rheumatology Department, Taipei Veterans General Hospital,
  • - Now, University lecturer, Medical department, National Yang-Ming Chiao Tung University.,
  • - , The chief resident physician, Allergy, Immunology and Rheumatology, Taipei Veterans General Hospital,
  • - , Attending physician, Hospitalist Ward, Taipei Veterans General Hospital,

• Medical Expertise

  1. Allergic-related diseases
  2. immune system disorders
  3. rheumatic diseases
  4. gout

• License

  Certification of Medical Licensure 

Certification of Internal Medicine 

Certification of Allergy & Immunology  

Certification of Rheumatology

[Publications]

1. Hung-Cheng Tsai, Chien-Fu Hsu, Chia-Chang Huang, Shiang-Fen Huang, Tzu-Hao Li, Ying-Ying Yang, Ming-Wei Lin, Tzung-Yan Lee, Chih-Wei Liu, Yi-Hsiang Huang, Ming-Chih Hou, Han-Chieh Lin. Propranolol Suppresses the T-Helper Cell Depletion-Related Immune Dysfunction in Cirrhotic Mice. Cells. 2020 Mar 3;9(3):604. (IF: 7.666)
2. Tsai HC, Liao HT, Tsai CY. Retroperitoneal Fibrosis With a Damaged Kidney in IgG4-Related Disease. J Clin Rheumatol. 2019 Oct 22. (IF: 3.650)
3. Tsai HC, Chang FP, Li TH, Liu CW, Huang CC, Huang SF, Yang YY, Lee KC, Hsieh YC, Wang YW, Lee TY, Huang YH, Hou MC, Lin HC. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice. Biomed Res Int. 2019 Jun 19;2019:6740616. (IF: 3.246)
4. Tsai HC, Li TH, Huang CC, Huang SF, Liu RS, Yang YY, Hsieh YC, Lee KC, Huang YH, Hou MC, Lin HC. Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension. Am J Pathol. 2018 Jul;188(7):1608-1624. (IF: 5.770)
5. Tsai HC, Yang YY. Pioglitazone decrease intrapulmonary shunt in biliary cirrhotic rats with hepatopulmonary syndrome. J Chin Med Assoc. 2017 Nov;80(11):679-680. (IF: 3.396)